Boumsell; Laurence

Patent Applications and Registrations

Patent applications and USPTO patent grants for Boumsell; Laurence.The latest application filed is for "angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2".

Company Profile

1.14.17

Boumsell; Laurence - Paris FR
Boumsell; Laurence - Creteil FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Angiogenic and Immunologic Applications of Anti-CD160 Specific Compounds Obtainable From mAb CL1-R2 App 20150004170 - Bensussan; Armand ; et al.	2015-01-01
ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 App 20140120110 - Bensussan; Armand ; et al.	2014-05-01
Compositions containing antibodies for treating CD5+ HLA-DR+ B or T cell related diseases Grant 8,679,500 - Boumsell , et al. March 25, 2	2014-03-25
Means for the diagnosis and therapy of CTCL Grant 8,518,655 - Bensussan , et al. August 27, 2	2013-08-27
Use Of An Anti-cd71 Antibody For Preparing A Medicament App 20130216476 - Boumsell; Laurence	2013-08-22
Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 Grant 8,444,978 - Bensussan , et al. May 21, 2	2013-05-21
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells Grant 8,409,573 - Boumsell , et al. April 2, 2	2013-04-02
Novel Means For The Diagnosis And Therapy Of Ctcl App 20120329063 - BENSUSSAN; ARMAND ; et al.	2012-12-27
Means for the diagnosis and therapy of CTCL Grant 8,268,308 - Bensussan , et al. September 18, 2	2012-09-18
Compositions Containing Antibodies For Treating Cd5+hla-dr+b Or T Cell Related Diseases App 20120121598 - Boumsell; Laurence ; et al.	2012-05-17
Use Of Anti-cd100 Antibodies App 20120027758 - Belin; Marie-Francoise ; et al.	2012-02-02
ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 App 20120003224 - Bensussan; Armand ; et al.	2012-01-05
Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells App 20110311544 - Boumsell; Laurence ; et al.	2011-12-22
Use of anti-CD100 antibodies for the treatment of inflammatory disorders affecting the central or peripheral nervous system Grant 8,067,247 - Belin , et al. November 29, 2	2011-11-29
Novel Means For The Diagnosis And Therapy Of Ctcl App 20110151472 - BENSUSSAN; ARMAND ; et al.	2011-06-23
Means for the diagnosis and therapy of CTCL Grant 7,919,085 - Bensussan , et al. April 5, 2	2011-04-05
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells Grant 7,736,647 - Boumsell , et al. June 15, 2	2010-06-15
Nucleic acids encoding CD100 molecules Grant 7,700,102 - Hall , et al. April 20, 2	2010-04-20
Use Of Soluble Cd160 To Suppress Immunity App 20100008932 - Bensussan; Armand ; et al.	2010-01-14
Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 App 20090317401 - Bensussan; Armand ; et al.	2009-12-24
Novel Means For The Diagnosis And Therapy Of Ctcl App 20080274468 - Bensussan; Armand ; et al.	2008-11-06
Means for the diagnosis and therapy of CTCL Grant 7,399,595 - Bensussan , et al. July 15, 2	2008-07-15
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells App 20060286030 - Boumsell; Laurence ; et al.	2006-12-21
Use of anti-cd100 antibodies App 20060233793 - Belin; Marie-Francoise ; et al.	2006-10-19
Novel means for the diagnosis and therapy of ctcl App 20050074761 - Bensussan, Armand ; et al.	2005-04-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.